BRIEF—Takeda spin-out raises $27 million in series B round

Chordia Therapeutics, a Kanagawa, Japan-based oncology startup, has raised $27 million in a series B financing round.

The firm was spun out of Takeda Pharmaceutical in late 2017, and previously raised $11 million.

The firm will use the money primarily to advance its lead asset, CTX-712, a selective pan-CDC-like kinase (“CLK”) inhibitor in Phase I testing.

Director Hiroyuki Ueno said: “I expect Chordia to continue pursuing patient-centric R&D through industry‐academia‐government collaboration and become a global company, based in Japan.”